Key Highlights

  • Vivani Medical (NASDAQ:VANI) was up 10.61 percent to USD 1.21, with SLIM-1 top-line data expected in November 2026.
  • OraSure Technologies (NASDAQ:OSUR) was down 8.63 percent to USD 3.60, ahead of third quarter results on November 9, 2026.
  • Accuray (NASDAQ:ARAY) was up 8.50 percent to USD 0.1519, with fiscal first-quarter results due November 4, 2026.
  • Jin Medical International (NASDAQ:ZJYL) was down 10.64 percent to USD 2.10, with first-half Revenue down 9.7 percent.
  • BioRestorative Therapies (NASDAQ:BRTX) was up 8.55 percent to USD 1.52, with Phase 2 topline data expected in the second quarter of 2027.

Vivani Medical (NASDAQ:VANI): A GLP-1 Implant Readout Is Guided for November

Vivani Medical (NASDAQ:VANI) was up 10.61 percent to USD 1.21 in pre-market trading on November 2, 2026. No press release or filing dated around that day was identified as the cause. The rise may reflect positioning ahead of a data event the company has already flagged.

The company said top-line data from the Phase 1 SLIM-1 trial of NPM-139 are expected in November 2026, with ten participants per arm. Cash was USD 20.8 million at June 30, 2026, and no cash runway was stated in the release reviewed. As a penny stock, it carries Volatility and dilution risks.

OraSure Technologies (NASDAQ:OSUR): Sliding Despite a Sickle Cell Announcement

OraSure Technologies (NASDAQ:OSUR) was down 8.63 percent to USD 3.60 in pre-market trading on November 2, 2026. No company announcement that explains a decline was identified. The only item dated that day was a press release saying the company joined the World Coalition on Sickle Cell Disease.

Second quarter 2026 revenue was USD 30.6 million, down 2 percent, and cash was USD 160.6 million at June 30, 2026. The company withdrew its InteliQuick CT/NG submission and plans a future one. Third quarter guidance is USD 29.5 million to USD 32.5 million, with results due November 9, 2026.

Accuray (NASDAQ:ARAY): A Sub-Dollar Bounce Before Earnings

Accuray (NASDAQ:ARAY) was up 8.50 percent to USD 0.1519 in pre-market trading on November 2, 2026. The implied prior close was about USD 0.14 (calculated). No announcement dated late October to November 2, 2026 was identified, so the move looks like a rebound in a deeply depressed share price.

The company reports fiscal first-quarter 2027 results on November 4, 2026. Fiscal 2026 net revenue was USD 401.9 million, down 12 percent, with a net loss of USD 49.2 million. Long-term debt, net, was about USD 146.4 million against USD 41.2 million of cash, and the sources reviewed did not confirm any specific Nasdaq notice.

Jin Medical International (NASDAQ:ZJYL): A Dip With No Stated Catalyst

Jin Medical International (NASDAQ:ZJYL) was down 10.64 percent to USD 2.10 in pre-market trading on November 2, 2026. No announcement dated late October to November 2, 2026 was identified, so the move is best read as ordinary small-cap volatility on thin pre-market volume.

Revenue for the six months ended March 31, 2026 was USD 8.9 million, down 9.7 percent, mainly on ceasing electric scooter sales and lower wheelchair orders from its largest Japanese customer. Gross Margin rose to 26.9 percent. The company reported a net loss of USD 0.2 million and holds USD 21.0 million of short-term investments.

BioRestorative Therapies (NASDAQ:BRTX): A Climb Ahead of the 2027 Spine Readout

BioRestorative Therapies (NASDAQ:BRTX) was up 8.55 percent to USD 1.52 in pre-market trading on November 2, 2026. The implied prior close was about USD 1.40 (calculated). No company announcement dated late October to November 2, 2026 was identified as the trigger.

About 99 patients were enrolled in the Phase 2 study of BRTX-100, and topline safety and efficacy data are expected in the second quarter of 2027. The May 26, 2026 release gave no cash balance or financing detail. As a Penny Stock with a history of funding clinical work through share issuance, it carries dilution risk.

Where Things Stand

The five companies sit at different points on the calendar. Accuray reports on November 4, OraSure on November 9, and Vivani guides to a readout during November, while BioRestorative's data are not expected until 2027. For most, no announcement dated November 2, 2026 was identified, so investors may watch upcoming filings, results and any Capital raising.